Nerve Transfer After Spinal Cord Injury- Multi-center

Sponsor
Washington University School of Medicine (Other)
Overall Status
Recruiting
CT.gov ID
NCT04023591
Collaborator
Stanford University (Other), University of Pennsylvania (Other), University of Michigan (Other), University of Calgary (Other), University of Utah (Other), United States Department of Defense (U.S. Fed), The Methodist Hospital Research Institute (Other)
70
8
79.6
8.8
0.1

Study Details

Study Description

Brief Summary

Current treatment strategies of acute cervical spinal cord injuries remain limited. Treatment options that provide meaningful improvements in patient quality of like and long-term functional independence will provide a significant public health impact. Specific aim: Measure the efficacy of nerve transfer surgery in the treatment of patients with complete spinal cord injuries with no hand function. Optimize the efficiency of nerve transfer surgery by evaluating patient outcomes in relation to patient selection and quality of life and functional independence.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Surgery/Occupational Therapy

Detailed Description

Study Design and Feasibility: A prospective multi-institutional non-randomized single arm design will be utilized. Seventy subjects with cervical ASIA A-B (International Standards for Neurological Classification of Spinal Cord Injury) SCI and hand function impairment that fit the International Classification for Surgery of the Hand 0-4 will be identified. Only patients with stable ASIA scores and no evidence of functional improvement in motor or sensory examination for at least 3 months will be recruited. All patients will undergo Electromyography (EMG) and nerve conduction studies (NCS) to verify intact innervation (normal compound muscle action potentials (CMAPs)) to the paralyzed target muscles below the level of injury. Functional electrical stimulation (FES) will be used to verify loss of lower motor neuron function in key muscle groups in the zone of injury and help differentiate those muscle with intact connections to preserve anterior horn cells. Only those patients with clinically normal, Medical Research Council (MRC) muscle grade 5/5 donor (axonal donor) function will be enrolled.

Outcome Measures Primary Outcome Measures: Pre- and Post-operative upper motor strength. (Manual motor testing & Hand Held Dynamometry) Secondary Outcome Measures: Disabilities of the Arm, Shoulder, and Hand (DASH), Michigan Hand Questionnaire (MHQ), Spinal Cord Injury Quality of Life (SCIQOL), GRASSP test (pre-operative, post-operatively - 6 months, 12 months, and 24 months, 36 months and 48 months), rates of intraoperative and post-operative complications, and rates of reoperation.

Rehabilitation and hand therapy are critical components of motor re-education following nerve transfers. Cortical plasticity and motor remapping occurs following nerve transfers allowing independent functional control of the recipient muscles. All patients will begin rehabilitation and hand therapy beginning 2 weeks after surgery. They undergo one hour of hand therapy and occupational therapy for motor re-education once to twice a week for 48 months following surgery. Rehabilitation will be phased to early and late - added exercises focusing on co-contraction, repetition, and range of motion will be included as home therapy.

Study Design

Study Type:
Observational
Anticipated Enrollment :
70 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Nerve Transfers to Improve Upper Extremity Function and Quality of Life in Tetraplegic Patients
Actual Study Start Date :
Apr 13, 2020
Anticipated Primary Completion Date :
Mar 1, 2026
Anticipated Study Completion Date :
Dec 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Surgery

Surgery/ Occupational Therapy

Procedure: Surgery/Occupational Therapy
Surgery based on function and injury/ Occupational therapy for 48 months post-surgery

Outcome Measures

Primary Outcome Measures

  1. Manual Motor Testing [48 months]

    Change from baseline testing strength of upper extremities at 48 months post-operatively

  2. Handheld Dynamometry [48 months]

    Change from baseline grip strength at 48 months post-operatively

Secondary Outcome Measures

  1. Change in Disabilities of Arm, Shoulder and Hand (DASH) scores [48 months]

    Change from baseline DASH scores at 48 months post-operatively. Scores range from 0-100 with 0 being the most positive score representing no arm, shoulder or hand disability and 100 being the lowest score indicating the most severe arm, shoulder and hand disability.

  2. Change in Spinal Cord Injury Quality of Life (SCIQOL) scores [48 months]

    Change in baseline SCIQOL scores at 48 months post-operatively. Five scores of 0-30 (0=less satisfied and 30=most satisfied) are calculated: 1. Total Quality of Life; 2. Health and Functioning Subscale; 3. Social and Economic Subscale; 4. Psychological/Spiritual Subscale; 5 Family Subscale. Calculation of scores weighs satisfaction scores according to level of importance assigned to each item. An overall score can be obtained by summing the scores for all six scales after reversing the pain scale and dividing by six.

  3. Rates of Intra-operative and post-operative complications [48 months]

    The number of complications within and after the operation

  4. Hand Function, measured by the GRASSP test [48 months]

    Change in baseline GRASSP Test results for hand function at 48 months post-operatively

  5. Changes in the Graded Redefined Assessment of Strength, Sensation and Prehension scores (GRASSP) [48 months]

    Change in baseline GRASSP results for strength, sensation and prehension at 48 months post-operatively. Five subtests: 1. Dorsal sensation (3 locations) each scored 0-4 (sum =subtest score, 0-12, with 0 being no sensation and 12 being normal sensation); 2. Palmar sensation (same as above); 3. Strength (10 muscles of arms and hand), motor grad 0-5 for each (sum = subtest total 0-50 with 0 being worst score and 50 being full motor function in all muscles); 4. Prehension ability - 3 grasps (cylindrical, lateral key, tip to tip) - each scored 0-4 (sum=subtest score, 0-12 with 0 being worst function and 12 being no dysfunction); 5 Prehension performance - 6 prehension tasks (pour water, open jars, pick up and turn key, transfer 9 pegs from board, pick up four coins and place in slot and screw 4 nuts on bolt - each scored 0-5 (sum=subtest score 0-30 with 0 being worst score to 30 being best possible score.

  6. Neuro Quality of Life - Depression Short Form (NQOL-Dep) [48 months]

    Changes in baseline NQOL-Dep scores at 48 months post-operatively. Scores range from 8-40 with 8 being best outcome and 40 being the worst outcome

  7. Neuro Quality of Life - Upper Extremity Short Form (NQOL-UEF) [48 Months]

    Changes in baseline NQOL-UEF scores at 48 months post-operatively. Scores range from 8-40 with 40 being the best outcome and 8 being the worst possible outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria

  1. Age 18-65, inclusive

  2. At least 3 months of non-operative rehab therapy

  3. Mentally and physically willing and able to comply with evaluations

  4. Less than 36 months post-injury

  5. Stable ASIA scores with no evidence of functional improvement in motor or sensory examination for at least 3 months

  6. ASIA A or B determined by the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)

  7. EMG/NCS verifies intact innervation (normal CMAPs) to the paralyzed target muscles below the level of injury

  8. Functional electrical stimulation (FES) will be performed. Subject must have clinically normal MRC grade 5/5 donor (axonal) function

  9. Injury Level C4-C8

Exclusion Criteria

  1. Active infection at the operative site or systemic infection

  2. Any return or ongoing clinical recovery of distal motor function

  3. Mentally or physically compromised that will prevent them from complying with evaluations.

  4. Immunologically suppressed

  5. Currently undergoing long-term steroid therapy

  6. Active malignancy

  7. Pregnant

  8. Significant joint contractures and/or limitations in passive range of motion in the arm or hand, per treating surgeon's discretion

  9. Lack of appropriate social support and/or infrastructure to commit to scheduled follow-up visits.

  10. Patients who are planning on undergoing a tendon transfer during the study period or who have had a tendon transfer in the past.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stanford University Stanford California United States 94305
2 University of Michigan Ann Arbor Michigan United States 48109
3 Washington University Saint Louis Missouri United States 63110
4 University of Pennsylvania Philadelphia Pennsylvania United States 19104
5 Houston Methodist Houston Texas United States 77030
6 The University of Texas Houston Health Science Center Houston Texas United States 77030
7 University of Utah Salt Lake City Utah United States 84132
8 Alberta Health Services - Foothills Medical Center Calgary Alberta Canada T2N 2T9

Sponsors and Collaborators

  • Washington University School of Medicine
  • Stanford University
  • University of Pennsylvania
  • University of Michigan
  • University of Calgary
  • University of Utah
  • United States Department of Defense
  • The Methodist Hospital Research Institute

Investigators

  • Principal Investigator: Wilson Z Ray, MD, Washington University School of Medicine

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT04023591
Other Study ID Numbers:
  • SC180063
First Posted:
Jul 17, 2019
Last Update Posted:
Jul 19, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Washington University School of Medicine
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 19, 2022